KalVista Pharmaceuticals (KALV) Net Income towards Common Stockholders Growth (5y) (2021 - 2025)
KalVista Pharmaceuticals (KALV) Net Income towards Common Stockholders Growth (5y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -32.40% |
| Apr 30, 2025 | -47.33% |
| Oct 31, 2024 | -37.01% |
| Jul 31, 2024 | -33.02% |
| Apr 30, 2024 | 35.99% |
| Jan 31, 2024 | -35.89% |
| Oct 31, 2023 | -50.71% |
| Jul 31, 2023 | -39.90% |
| Apr 30, 2023 | -115.17% |
| Jan 31, 2023 | -48.19% |
| Oct 31, 2022 | -49.49% |
| Jul 31, 2022 | -50.55% |
| Apr 30, 2022 | -68.66% |
| Jan 31, 2022 | -36.96% |
| Oct 31, 2021 | -51.05% |
| Jul 31, 2021 | -37.62% |